How UiPath (PATH) Is Using Agentic AI to Tackle Healthcare Payment Bottlenecks

UiPath, Inc. (NYSE:PATH) is one of the cheap AI stocks to buy in 2026.

On February 23, 2026, UiPath announced a suite of agentic AI solutions for healthcare providers and payers, targeting administrative and financial bottlenecks tied to revenue cycle management. The company said the initial offerings focus on medical records summarization, claim denial prevention and resolution, and prior authorization, using agentic automation and orchestration with governed agents designed for regulated workflows.

UiPath framed the launch around common payer-provider friction, including labor shortages and disconnected systems, and positioned the tools as a way to translate complex clinical documentation into structured, decision-ready outputs that can speed reimbursement processes. In a customer example included in the announcement, a firm, medlitix, said it reduced the average summary review time from 70 minutes to 6 minutes after implementing UiPath’s Medical Records Summarization solution, describing that as a 90% improvement. UiPath also said it is partnering with Genzeon to deliver the prior authorization solution, noting Genzeon’s selection by CMS for the WISeR Model and citing Genzeon’s payer experience across more than 100 healthcare clients and 30+ disease-specific clinical models.

UiPath, Inc. (NYSE:PATH) is a software company focused on automation and orchestration, offering a platform that helps organizations deploy and manage automated workflows, including AI agent-led processes, across enterprise systems.

While we acknowledge the potential of PATH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.